| MGGIX | RNPEX | MGGIX / RNPEX | |
| Total Expense Ratio | 0.93 | 0.76 | 122% |
| Annual Report Gross Expense Ratio | 0.93 | 0.76 | 122% |
| Fund Existence | 18 years | 24 years | - |
| Gain YTD | 2.350 | 14.382 | 16% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000000 | 250 | 400,000% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 3.28B | 163B | 2% |
| Annual Yield % from dividends | 0.00 | 0.46 | - |
| Returns for 1 year | -0.25 | 11.74 | -2% |
| Returns for 3 years | 76.66 | 51.95 | 148% |
| Returns for 5 years | -19.62 | 20.88 | -94% |
| Returns for 10 years | 117.54 | 98.22 | 120% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| EMSLX | 18.99 | 0.07 | +0.37% |
| Shelton Emerging Markets Investor | |||
| LEAIX | 15.61 | 0.03 | +0.19% |
| Lazard Emerging Markets Eq Advtg Instl | |||
| CSSAX | 33.40 | 0.06 | +0.18% |
| Carillon Chartwell Small Cap A | |||
| PPUPX | 14.36 | 0.02 | +0.14% |
| Principal LargeCap Growth I R5 | |||
| FBTAX | 38.86 | N/A | N/A |
| Fidelity Advisor Biotechnology A | |||